# HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer

> **NCT06389500** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Harbin Medical University** · enrollment: 30 (estimated)

## Conditions studied

- Biliary Tract Cancer

## Interventions

- **DRUG:** Adebrelimab
- **DRUG:** Lenvatinib
- **PROCEDURE:** Hepatic Arterial Infusion Chemotherapy

## Key facts

- **NCT ID:** NCT06389500
- **Lead sponsor:** Harbin Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-05-01
- **Primary completion:** 2027-05-01
- **Final completion:** 2028-05-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06389500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06389500, "HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06389500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*